国药股份(600511) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥13,747,350,727.81, representing a year-on-year increase of 3.58%[4] - The total profit for the period was ¥707,162,533.10, reflecting a year-on-year growth of 9.13%[4] - The net profit attributable to shareholders was ¥543,717,921.74, which is a 13.10% increase compared to the same period last year[4] - The basic earnings per share for the quarter was ¥0.7206, up by 13.10% year-on-year[5] - Total operating revenue for the first three quarters of 2025 reached ¥39.38 billion, an increase of 3.56% compared to ¥38.03 billion in the same period of 2024[20] - Net profit for the first three quarters of 2025 was ¥1.56 billion, slightly down from ¥1.57 billion in 2024, representing a decrease of 0.66%[21] - Earnings per share for the first three quarters of 2025 were ¥1.9778, compared to ¥1.9632 in the same period of 2024, indicating a growth of 0.75%[22] - The net profit for the first three quarters of 2025 was ¥1,260,310,854.59, representing a growth of 8.2% from ¥1,164,577,361.68 in the first three quarters of 2024[31] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥35,125,161,234.99, showing a slight increase of 0.56% from the end of the previous year[5] - The total assets of the company as of September 30, 2025, amounted to ¥25.03 billion, a decrease from ¥26.82 billion at the end of 2024[27] - The company's current assets totaled RMB 30,528,913,480.03, slightly up from RMB 30,356,823,125.08 in the previous period[15] - The total liabilities decreased to RMB 20,000,000,000 from RMB 21,000,000,000, indicating a reduction of about 4.8%[15] - The company's total liabilities decreased to ¥15.19 billion in 2025 from ¥15.95 billion in 2024, a reduction of 4.77%[18] - The total liabilities decreased from ¥12,992,254,186.56 to ¥10,517,805,019.29, indicating a reduction of approximately 18.6%[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,584[10] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., holds 54.72% of the shares, amounting to 412,841,745 shares[10] Cash Flow - The company reported a net cash flow from operating activities of ¥-2,050,432,782.11 for the year-to-date[4] - Cash inflow from operating activities for the first three quarters of 2025 reached ¥40.19 billion, compared to ¥39.56 billion in the same period of 2024, reflecting an increase of approximately 1.8%[24] - Net cash outflow from operating activities was ¥2.05 billion in 2025, worsening from a net outflow of ¥1.03 billion in 2024[25] - The cash flow from operating activities for the first three quarters of 2025 was ¥66,823,988.11, a decline of 82.1% compared to ¥372,998,879.56 in the same period of 2024[34] Investment and Expenses - Investment income for the first three quarters of 2025 was ¥440.99 million, an increase of 39.3% from ¥316.41 million in 2024[21] - Research and development expenses for the first three quarters of 2025 were ¥43.59 million, slightly down from ¥44.14 million in 2024, a decrease of 1.25%[20] - The company reported a financial expense of -¥16.58 million in 2025, a significant improvement compared to -¥73.67 million in 2024[20] - The financial expenses showed a significant improvement, with a net financial income of ¥5,952,984.57 in 2025 compared to a loss of ¥54,920,861.91 in 2024[30] Other Comprehensive Income - Non-recurring gains and losses for the period totaled ¥5,074,780.26, with significant contributions from government subsidies and asset disposals[8] - Other comprehensive income after tax for the first three quarters of 2025 was ¥25,861,163.15, compared to a loss of -¥4,446,206.50 in the same period of 2024[31]